

On-Demand Chemically Reconfigurable Biofilm Microbial Hydrogels for Antibiotic Assay

Le Hoang Phu Pham¹, Khanh Ly¹, Hao Wang², Sang Won Lee², Yi Wang², K. Scott Phillips², and Xiaolong Luo¹

¹School of Engineering, The Catholic University of America. ²Division of Biology, Chemistry and Materials Science, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, US Food and Drug Administration



FDA

Abstract

- Device-associated infections are responsible for more than 50,000 deaths per year and are linked to Center for Disease Control and Prevention (CDC) priority antibiotic-resistant bacteria. These infections involve bacterial biofilms, which are difficult to treat with antimicrobials, in some cases exceeding 10,000 times the minimal inhibitory concentration (MIC)
- Most pharmaceutical interventions do not take into account the impact and role of biofilm, biomaterials colonization or necrotic tissue in their performance testing methodology. Currently there are no established methods to study the difference between genetic resistance of bacteria to antibiotics and phenotypic resistance of bacteria living in biofilm communities to antibiotics
- In this work we develop a method to study biofilm in alginate hydrogels that can be dissolved, allowing for measurement of both resistance and persistence to antibiotics, with the goal of developing more effective interventions for device associated infections

Introduction

- Antibiotic resistance threatens to usher in a return to the pre-penicillin era of unchecked infections
- Carbapenem-resistant *Enterobacteriaceae*, Methicillin-resistant *Staphylococcus aureus*, drug-resistant *Streptococcus pneumoniae*, and multidrug-resistant *Pseudomonas aeruginosa*, all are CDC urgent or serious threats, are found in infections associated with medical device use
- Current testing is based on planktonic bacterial susceptibility models




Figure 1. Schematics of several characteristics of biofilm's protective barrier and the embedded microbes leading to resistance to antibiotics

Table 1. Strains of bacteria used in this study

Bacterial Strain	Genetic Construct	Phenotype
<i>Escherichia coli</i>	RP437/pRSH103	Red Fluorescence
	XEN14	Bioluminescence
<i>Pseudomonas aeruginosa</i>	PAO1/pTdK-GFP	Green Fluorescence
<i>Staphylococcus aureus</i>	AH2547/pCM29	Green Fluorescence

Materials and Methods

- Bacterial strains (Table 1) inoculated into 2% w/v alginate + 2× Mueller Hinton (MHB) broth (5×10⁵ CFU per hydrogel)
- Bacterial alginate hydrogel was formed using spraying technique of CaCl₂ (Fig. 2A)
- Viability assessment using 1000× antibiotics was quantified by microplate reader and verified by dissolving the gel for agar plating
- Confocal microscopy to assess the formation of biofilm balls
- Ruby Biofilm Stain to verify the biofilm matrix





Figure 2. (A) Schematics of formation of alginate biofilm gel and experiment setup. (B) Molecular structure of alginate polysaccharide chains crosslinked by calcium ions. (d) – (e) Confocal images of biofilm balls and 3D reconstruction in alginate gel. (f) – (g) Biomatrix and cell staining

Results and Discussion

- Confocal microscopy shows the formation of biofilm balls (Fig. 2d-e)
- Stains show biofilm matrix enveloping the cells within (Fig. 2f-g)
- MIC testing was performed to obtain a baseline for the interaction of each strain with antibiotics (Table 2)
- Fig. 3a-c, fluorescence signals from hydrogels cultured with MHB, confirmed with plating viability, showed the bacterial biofilms stayed viable over 3 days




Figure 3. Fluorescence/Bioluminescence signals of (a) *E. coli* RP437/pRSH103, (b) *E. coli* Xen14, (c) *P. aeruginosa* PAO1/pTdK-GFP, (d) *S. aureus* AH2547/pCM29, and (e) *E. coli* Xen14 treated with MHB (negative control), bleach (positive control), and different antibiotics from day 0 to day 3. Plating viability is presented as (+) for live and (-) for dead

- Fig. 3a, inconsistency between the high fluorescence signal and the no viability at day three is of particular concern
- Fig. 3b – c, in bleach treatment, vital signs were detected on day 1 suggesting the strong persistent nature of biofilm in the healthcare environment and thus the need for rigorous cleaning with extended exposure times
- Fig. 3c, fluorescence signal detected with biofilms treated with ciprofloxacin on day 3, suggests there is a lag between loss of bacterial culturability and the loss of fluorescent signal. This could be due to slow degradation of fluorophores or due to viable but non-culturable bacteria—further investigation is needed
- Fig. 3d, persistent bacteria in biofilm may be metabolically inactive, resulting in poor expression of the luciferin-luciferase system; this raises concerns about the reliability of bioluminescence for quantification of culturable bacteria

Table 2. MIC obtained antibiotics tested with bacterial strains and the reference range for each drug with related ATCC bacterial strains

Bacterial Strain	Antibiotic	Ampicillin	Ciprofloxacin	Chloramphenicol	Tetracycline	Vancomycin
		MIC (μg/mL)	MIC (μg/mL)	MIC (μg/mL)	MIC (μg/mL)	MIC (μg/mL)
<i>E. coli</i>	RP437/pRSH103	4	0.035	4	128	128
	XEN14	128	0.035	2	0.5	128
	ATCC25922 ¹	8 – 32	0.25 – 1	8 – 32	4 – 16	N/A
<i>P. aeruginosa</i>	PAO1/pTdK-GFP	512	1	>512	128	>512
	ATCC27856 ¹	N/A	0.5 – 2	N/A	N/A	N/A
<i>S. aureus</i>	AH2547/pCM29	0.5	0.125	64	0.5	1
	ATCC29213 ¹	N/A	1 – 4	8 – 32	4 – 16	2 – 16

¹Information of reference strains and MIC ranges obtained from CLSI M100, 29th.

N/A: the antibiotic is not considered for treatment

Conclusion

- Developed and characterized a hydrogel assay that was able to form a robust bacterial biofilm
- Found several anomalies between the culture results (gold standard) and the spectroscopic results
- Future works will focus on DNA sequencing and gene expression with in-depth antibiotic resistance studies

Acknowledgement

- Special thanks to ORISE Research Participation Program at FDA that made the project possible

Disclaimer

The findings and conclusions in this poster have not been formally disseminated by the US FDA and should not be construed to represent any agency determination or policy. The mention of commercial products, their sources, or their use in connection with material reported herein is not to be construed as either an actual or implied endorsement of such products by the DHHS